Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03319823
Other study ID # 48809
Secondary ID
Status Withdrawn
Phase Phase 4
First received
Last updated
Start date October 25, 2017
Est. completion date February 1, 2021

Study information

Verified date February 2021
Source Cedars-Sinai Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a protocol to obtain pilot data to submit a new NIH grant on Nocturnal Hypertension and Nocturia. In the diversity supplement to Dr. Victor's current NIH grant (Cut Your Pressure Too: The Los Angeles Barbershop Blood Pressure Study) the results show that uncontrolled systolic hypertension is an independent determinant of nocturia in African American men. the investigators now want to pursue this correlation by designing a new NIH grant proposal to determine whether replacing short acting with long acting drugs and dosing them at bedtime rather than in the morning will: A. Lower systolic blood pressure during sleep B. Improve nocturia and result in better sleep quality


Description:

Aims and Significance of pilot data Determine: 1. The feasibility of the Southern California Healthy Heart and Blood Pressure registry as an effective method to recruit African American men to participate in a new research program 2. If participants are willing to comply with the study procedures including wearing an activity monitor, sleep study device, and ambulatory blood pressure monitor 3. The within subject variation for repeated measures of nocturnal blood pressure by ambulatory blood pressure and activity monitoring 4. If nocturnal systolic blood pressure is higher in men with self-reported nocturia ≥2 than in men with 0-1 nocturia 5. If use of long-acting antihypertensive medication as well as nighttime dosing of medication can lower nocturnal systolic blood pressure and reduce nocturia Purpose: Obtain key pilot data to show feasibility and document the reproducibility of the proposed measurements.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 1, 2021
Est. primary completion date February 13, 2019
Accepts healthy volunteers No
Gender Male
Age group 35 Years to 59 Years
Eligibility Inclusion Criteria: - African American Men - Age 35 to 59 years-old - Able to give informed consent - Willing to wear the activity monitor, ambulatory blood pressure monitoring (ABPM), and sleep study device - Uncontrolled hypertension: both a sleeping average systolic blood pressure of = 125 mm Hg and an awake average systolic blood pressure of = 135 mm Hg Exclusion Criteria: - Severe Sleep Apnea (Apnea Hypopnea Index (AHI) of > 30 on home sleep study) or history of sleep apnea diagnosis and use of Continuous Positive Airway Pressure therapy - Uncontrolled Diabetes Mellitus (a random glucose of = 200 mg/dL) - History of diagnosis or symptoms of either prostate disease or overactive bladder (urinary urgency or frequency during the daytime) - Chronic kidney disease (Glomerular filtration rate of < 60 mL/min/1.73 m2 based on the MDRD equation) - Renal transplant recipient - Loop diuretic use - Night shift work - On chemotherapy for cancer - Orthostatic hypotension o After 2 minutes of standing: a drop in blood pressure of > 20/10 mm Hg, a standing systolic blood pressure of < 100 mm Hg, or tachycardia with an increased heart rate of > 20 beats/minute - Other reasons deemed unsafe for study participation by Principle Investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Thiazide Treatment Group
Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure <160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation. If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment
Intensified Thiazide Treatment Group
At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure >120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure >120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is <120.
Combination Medication Treatment Group
Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of = 140 mm Hg, or awake systolic blood pressure of = 160 mm Hg Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility If sleep systolic blood pressure is > 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy.

Locations

Country Name City State
United States Cedars-Sinai Medical Center Los Angeles California

Sponsors (1)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Participant Compliance If participants are willing to comply with the study procedures including wearing an activity monitor (it is built in the ambulatory blood pressure monitor), sleep study device, and ambulatory blood pressure monitor 12 weeks
Primary change in the systolic blood pressure in participants The within subject variation in millimeter of mercury for repeated measures of nocturnal systolic blood pressure by ambulatory blood pressure. Change from Baseline Systolic Blood Pressure at 12 weeks
Primary change nocturnal systolic blood pressure in relation with frequency of nocturia measurement of nocturnal systolic blood pressure will occur with continuous ambulatory blood pressure monitors. nocturia frequency will be self reported by participant and then verified by activity monitor (actigraph) built in the ambulatory blood pressure monitor . change from baseline at 12 weeks after treatment initiation.
Primary Night time blood pressure medication dosing in relation with frequency of Nocturia the use of long-acting antihypertensive medication as well as nighttime dosing of medication can lower nocturnal systolic blood pressure and reduce the frequency of nocturia which will be self reported by participant and then verified by activity monitor (actigraph) built in the ambulatory blood pressure monitor . Change of systolic blood pressure from baseline at 12 weeks.
See also
  Status Clinical Trial Phase
Completed NCT03812614 - Comparative Effectiveness of Family vs. Individually Focused Diabetes Education and Support N/A
Completed NCT03650166 - High BP and Home Monitoring Experience (HoME) Study N/A
Recruiting NCT02908139 - Noninvasive Perioperative Monitoring of Arterial Stiffness, Volume and Nutritional Status in Stable Renal Transplant Recipients N/A
Completed NCT01622400 - Efficacy of a Dedicated Therapeutic Education Program in Patients at High Cardiovascular Risk N/A
Completed NCT00659672 - Effect of Whey Protein on Blood Pressure N/A
Completed NCT00473681 - Intervention Study to Control High Blood Pressure for Korean American N/A
Completed NCT03542240 - Effects of Curcumin Supplementation on Gut Barrier Function in Patients With Metabolic Syndrome N/A
Active, not recruiting NCT05526092 - OAT-GUT-BRAIN: Effects of Oats and Rice on Comprehensive Health of Metabolically Challenged Individuals N/A
Completed NCT02218931 - ESTEEM - Effect of Simple, Targeted Diet in Pregnant Women With Metabolic Risk Factors on Pregnancy Outcomes N/A
Recruiting NCT03753204 - Salt-Sensitivity and Immunity Cell Activation Phase 1/Phase 2
Completed NCT04479384 - The Immediate Effect of an Osteopathic Manual Treatment on Blood Pressure in Adults With Hypertension - a Pilot Study. N/A
Not yet recruiting NCT04064281 - The Healthy Cantonese Diet on Cardiometabolic Syndrome N/A
Completed NCT04082819 - MediBeat - HeartBeat Observation Trial N/A
Completed NCT03555344 - Effect of Mantra on Hypertensive Patients N/A
Completed NCT00689819 - Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients N/A
Completed NCT00417170 - Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome Phase 2
Completed NCT00130156 - Effects of Combination Therapy With Alpha-1 Blocker (Bunazosin or Doxazosin) in the Treatment of Patients With Mild to Moderate Essential Hypertension Phase 4
Completed NCT05808556 - Sticker Pad Containing Essential Oil in Volunteer With High Blood Pressure N/A
Recruiting NCT05321368 - A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities N/A
Not yet recruiting NCT03686657 - Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients Phase 1/Phase 2